FoundationOne CDx test
| FoundationOne CDx test | |
|---|---|
| Term | FoundationOne CDx test |
| Short definition | Fotivda (foh-TIV-dah) A drug used to treat adults with advanced renal cell carcinoma (a type of kidney cancer). It is used in patients whose cancer has come back (came back) or has not improved after treatment with at least two other systemic therapies. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
FoundationOne CDx test - (pronounced) (Fown-DAY-Avoid…) A laboratory test performed on a sample of tumor tissue to match a patient's tumor to a specific drug or therapy. A FoundationOne CDx test looks at many different genes in the tissue sample to determine if a patient's tumor has a specific gene mutation (change) or biomarker that is targeted by a specific drug or therapy. This helps determine if the drug could be an effective treatment for the patient's tumor. A FoundationOne CDx test is a type of companion diagnostic test. FoundationOne is a registered trademark of Foundation Medicine, Inc. Also referred to as the F1CDx test
External links
- Medical encyclopedia article on FoundationOne CDx test
- Wikipedia's article - FoundationOne CDx test
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski